Overview

A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Cutia Therapeutics（Wuxi）Co.,Ltd